Recent news on Denileukin Diftitox

Eisai acquires US oncology expert Morphotek for $325 million  -  Mar 23, 2007
Pharma Times (subscription),They were Ontak (denileukin diftitox) and Targretin (bexarotene) capsules and gel for T cell lymphoma, and Panretin (alitretinoin) gel, used to treat the

Eisai Taking Over Morphotek; $325M For Antibody Foothold  -  Mar 22, 2007
BioWorld Online,The deal involved the marketed products Ontak (denileukin diftitox), for cutaneous T-cell lymphoma; Targretin (bexarotene) gel and capsules, also for CTCL;

Clinicians Introduce Guidelines for Diagnosis and Treatment of ...  -  Mar 21, 2007
DG NewsFor patients being treated with palliative intent, second-line therapy includes denileukin diftitox, gemcitabine, alemtuzumab, or GDP (gemcitabine,

Ligand Pharmaceuticals Announces Fourth Quarter Results  -  Mar 16, 2007
PharmaLive.com (press release),The sale included Ligand's four marketed oncology drugs ONTAK(R) (denileukin diftitox), Targretin(R) (bexarotene) capsules, Targretin(R) (bexarotene) gel 1%

Ligand Pharmaceuticals Announces Fourth Quarter Results  -  Mar 15, 2007
Business Wire (press release),The sale included Ligand’s four marketed oncology drugs ONTAK® (denileukin diftitox), Targretin® (bexarotene) capsules, Targretin® (bexarotene) gel 1% and

Melanoma :: Scientists harness diptheria toxin and interleukin 2 ...  09 Nov 2006
In the first part of a phase II clinical trial to test the drug denileukin diftitox (also known as DAB(389)IL2 or ONTAK) in melanoma, five out of seven ... -SpiritIndia, Scientists harness diptheria toxin and immune factor to fight ...  09 Nov 2006
In research with mice, Chesney’s team discovered that the drug denileukin diftitox targets and depletes regulatory T-cells, allowing particular T-cells in ... -U Of L News, Eisai Announces Completion of Acquisition of Four Oncology-Related ...  Oct 25, 2006
...obtained exclusive global rights to ONTAK(R) (denileukin diftitox), Targretin(R) (bexarotene) capsules, Targretin(R) (bexarotene) gel 1% and Panretin(R ... -PR Newswire (press release), Ligand Completes Sale of Oncology Product Lines  Oct 25, 2006
The sale includes Ligand’s four marketed oncology drugs: ONTAK® (denileukin diftitox), Targretin® (bexarotene) capsules, Targretin® (bexarotene) gel 1 ... -Business Wire (press release), Ligand Completes Sale of Oncology Product Lines  Oct 25, 2006
The sale includes Ligand's four marketed oncology drugs: ONTAK(R) (denileukin diftitox), Targretin(R) (bexarotene) capsules, Targretin(R) (bexarotene) gel 1 ... -Genetic Engineering News (press release), Ligand Sells More Products: $205M For Cancer Portfolio  Sep 8, 2006
The agreement with Eisai involves Ontak (denileukin diftitox), for cutaneous T-cell lymphoma; Targretin (bexarotene) gel and capsules, also for CTCL; and ... -BioWorld Online

Eisai Acquires Four Oncology-Related Products from Ligand  Sep 8, 2006
...acquisition agreement with Ligand Pharmaceuticals in which Eisai obtained exclusive global rights for ONTAK® (denileukin diftitox), Targretin® (bexarotene ... -PipelineReview.com

Eisai Acquires Four Oncology-Related Products From Ligand  Sep 7, 2006
California, Chairman and interim CEO: Henry F. Blissenbach) in which Eisai obtained exclusive global rights for ONTAK(R) (denileukin diftitox), Targretin(R ... -International News Service

Eisai Acquires Four Oncology-Related Products From Ligand  Sep 7, 2006
Chairman and interim CEO: Henry F. Blissenbach) in which Eisai obtained exclusive global rights for ONTAK® (denileukin diftitox), Targretin® (bexarotene ... -Yahoo! News

Scientists Harness Diptheria Toxin And Interleukin 2 To Help The ...  -  Nov 14, 2006
Haber Sağlık,In the first part of a phase II clinical trial to test the drug denileukin diftitox (also known as DAB(389)IL2 or ONTAK) in melanoma, five out of seven

Thyrotoxicosis Seen After Denileukin Diftitox Therapy  Jun 29, 2006
NEW YORK JUN 28, 2006 (Reuters Health) - Patients with mycosis fungoides treated with denileukin diftitox may develop acute thyrotoxicosis, warn clinicians in ... -Cancerpage.com

ODAC Committee to Meet Nov. 8 On Accelerated Approval Commitments  Jun 30, 2006
...for Johnson & Johnson/Alza’s Doxil® (liposomal doxorubicin), MedImmune’s Ethyol® (amifostine), Seragen’s Ontak® (denileukin diftitox), SkyePharma’s ... -Cancer Consultants



Experts See Need for Further Study of Insomnia and Sleep Aids like ...  Apr 24, 2006
...have caused chronic cases of the very same condition the drugs were designed to treat; (3) loss of color vision caused by ONTAK (denileukin diftitox), a drug ... - Newsinferno.com





FDA MedWatch - Ontak (denileukin Diftitox) Associated with Loss OF ...  Mar 16, 2006
ROCKVILLE, Md., March 15, 2006-Ligand Pharmaceuticals and FDA notified healthcare professionals of changes to the WARNINGS section of the prescribing ... - PharmaLive.com

Sanofi Will Be Losing Sleep over Potential Wave of Ambien Claims  Mar 16, 2006
...caused chronic cases of the very same condition the drugs were designed to treat; and (3) loss of color vision caused by ONTAK (denileukin diftitox), a drug ... - Newsinferno.com

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional